Enzon Pharmaceuticals gets tenders for $137.581 million 4.5% convertibles due 2009

By Jennifer Chiou

New York, July 6 - Enzon Pharmaceuticals, Inc. announced it received tenders from holders of $137.581 million of notes in the offer to buy up to its $180 million of its 4.5% convertible subordinated notes due 2008.

The tender expired at 5 p.m. ET on July 5. It began on June 6.

The company said it will pay $965.00 for each $1,000 principal amount of notes, plus accrued interest.

Enzon added that $122.642 million of notes remains outstanding.

Goldman, Sachs & Co. is the dealer manager (800 828-3182 or call collect 212 357-7867). D.F. King & Co., Inc. is the information agent (800 290-6427 or call collect 212 269-5550).

Based in Bridgewater, N.J., Enzon is a biopharmaceutical company focused on cancer. It markets Abelcet and Oncaspar.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.